Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class, masked, ...
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its ...
Jimmy Carter, ex-U.S President who turned 100, survived brain cancer for 9 years; here's how he did it
Former US President Jimmy Carter, who was diagnosed with melanoma that spread to his brain in 2015, has survived for nine ...
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...
2minutemedicine.com4d
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...
Medscape4d
FDA Panel Votes for Limits on Gastric, Esophageal Cancer Immunotherapy
After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...
Cancer spread to Jimmy Carter's brain 9 years ago. Here's how he's lived so long.
A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.